Ongoing Studies Investigating Rectal Spacer Benefits in Patients With Prostate Cancer Undergoing Radiation Therapy

Dr Daniel Allan Hamstra highlights ongoing and planned trials investigating rectal spacers in patients with prostate cancer undergoing radiation therapy that he hopes will provide more data on toxicity reduction and preservation of sexual function.

EP: 1.The Role of Rectal Spacers in Patients Undergoing Radiation Therapy for Prostate Cancer

EP: 2.Common Adverse Effects in Patients With Prostate Cancer Undergoing Radiation Therapy

EP: 3.Available Rectal Spacer Options for Patients With Prostate Cancer Undergoing Radiation Therapy

EP: 4.Rectal Separation for Prostate Cancer Radiation Therapy: Clinical Data on SpaceOAR and SpaceOAR Vue

EP: 5.Rectal Separation for Prostate Cancer Radiation Therapy: Clinical Data on Barrigel and BioProtect

EP: 6.Impact of Rectal Spacers on Sexual Quality-of-Life After Radiotherapy in Patients With Prostate Cancer

EP: 7.Recommendations for the Use of Rectal Spacers in Clinical Practice for Patients With Prostate Cancer

Now Viewing

EP: 8.Ongoing Studies Investigating Rectal Spacer Benefits in Patients With Prostate Cancer Undergoing Radiation Therapy

Related Videos

Related Content

Advertisement

May 19th 2025

Study shows value of precision-based approaches in prostate cancer

Hannah Clarke

The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke

Initial study results may be available as soon as the first half of 2026.

May 2nd 2025

Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

Hannah Clarke

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.

Related Content

Advertisement

May 19th 2025

Study shows value of precision-based approaches in prostate cancer

Hannah Clarke

The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke

Initial study results may be available as soon as the first half of 2026.

May 2nd 2025

Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

Hannah Clarke

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.